Valuation: Harbin Gloria Pharmaceuticals Co., Ltd

Market Cap 6.33B 950M 863M 797M 720M 1.36B 89.19B 1.41B 9.59B 3.8B 47.86B 3.56B 3.49B 152B P/E 2024
24.2x
P/E 2025 18.2x
Enterprise Value 5.49B 824M 749M 692M 625M 1.18B 77.39B 1.22B 8.32B 3.3B 41.53B 3.09B 3.03B 132B EV / Sales 2024
2.12x
EV / Sales 2025 2.82x
Free-Float
90.2%
Yield 2024 *
-
Yield 2025 -
Oct. 27 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Nine Months Ended September 30, 2026 CI
Aug. 26 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Half Year Ended June 30, 2026 CI
Apr. 27 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
Apr. 14 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Full Year Ended December 31, 2025 CI
Jan. 15 Harbin Gloria Pharmaceuticals Co., Ltd Approves Election of Xu Yuhong as Independent Director, Effective 14 January 2026 CI
25-10-28 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
25-08-26 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Half Year Ended June 30, 2025 CI
25-06-04 Harbin Gloria Pharmaceuticals Gets Right to Market Eisai's Mecobalamin Injection MT
25-05-27 Harbin Gloria Pharmaceuticals Signs Co-Promotion Deal for Lipid Drug MT
25-04-25 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-03-17 HARBIN GLORIA PHARMACEUTICALS Co., LTD Elects Liu Yueyin as A Non-Independent Director CI
25-03-14 Tranche Update on HARBIN GLORIA PHARMACEUTICALS Co., LTD's Equity Buyback Plan announced on October 22, 2024. CI
25-03-12 HARBIN GLORIA PHARMACEUTICALS Co., LTD's Equity Buyback announced on October 22, 2024, has closed with 32,307,224 shares, representing 1.42% for CNY 79.99 million. CI
1 day-1.39%
1 week-5.96%
Current month-2.07%
1 month-19.55%
3 months-37.31%
6 months-9.84%
Current year-7.49%
1 week 2.81
Extreme 2.81000000
3.1
1 month 2.8
Extreme 2.8
3.45
Current year 2.37
Extreme 2.37
5.1
1 year 2.37
Extreme 2.37
5.1
3 years 1.66
Extreme 1.66
5.1
5 years 1.66
Extreme 1.66
5.1
10 years 1.66
Extreme 1.66
9.8
Manager TitleAgeSince
Chief Executive Officer 53 2022-12-25
Corporate Officer/Principal 42 2018-04-17
Corporate Officer/Principal 40 2019-05-22
Director TitleAgeSince
Director/Board Member 40 2025-03-13
Director/Board Member 53 2022-11-10
Director/Board Member 42 2022-11-10
Date Insider Type Main position Quantity % Market Cap. Importance
7/2/25 Sell 587,500 0.0283%
7/2/25 Sell

Director

259,600 0.0125%
7/2/25 Sell 587,500 0.0283%
Change 5-day change 1-year change 3-year change Capi.($)
-1.39%-5.96%-17.92%+11.37% 963M
-1.17%-1.14%+38.59%+139.29% 1,275B
-1.14%-0.32%+40.23%+86.85% 680B
-0.72%-0.40%+25.10%+111.66% 521B
-0.95%+0.90%+41.16%+70.62% 389B
-0.92%-3.10%+54.49%+40.99% 356B
-1.80%-0.86%+26.04%+58.53% 305B
-1.90%-0.85%+1.28%+34.17% 287B
-1.43%-1.90%+33.56%+71.97% 250B
+1.00%-0.79%+36.61%+124.67% 208B
Average -1.08%-0.29%+27.91%+75.01% 427B
Weighted average by Cap. -1.05%+0.76%+34.96%+95.61%

Financials

2024 2025
Net sales 2.44B 366M 333M 307M 278M 524M 34.38B 542M 3.7B 1.46B 18.45B 1.37B 1.34B 58.43B 2.14B 320M 291M 269M 243M 458M 30.08B 474M 3.23B 1.28B 16.14B 1.2B 1.18B 51.12B
Net income 233M 34.91M 31.72M 29.31M 26.47M 49.96M 3.28B 51.71M 352M 140M 1.76B 131M 128M 5.57B 377M 56.53M 51.36M 47.46M 42.86M 80.89M 5.31B 83.74M 571M 226M 2.85B 212M 208M 9.02B
Net Debt -509M -76.3M -69.32M -64.05M -57.85M -109M -7.16B -113M -770M -305M -3.84B -286M -280M -12.18B -838M -126M -114M -106M -95.31M -180M -11.8B -186M -1.27B -503M -6.33B -472M -462M -20.06B
Projected Income Statement - Annual - Harbin Gloria Pharmaceuticals Co., Ltd
Logo Harbin Gloria Pharmaceuticals Co., Ltd
HARBIN GLORIA PHARMACEUTICALS Co Ltd is a China-based company principally engaged in the research, development, production and sale of pharmaceuticals. The Company operates its businesses through three segments. The Traditional Chinese Medicine segment's main product is Annao Pills and Tablets. The Chemical Pharmaceuticals segment's products include cardiovascular and cerebrovascular drugs, musculoskeletal drugs, vitamins, electrolytes, analgesics, anti-infectives, anti-tumor drugs and others. The Others segment engages in pharmaceutical research and development, clinical services and others. The Company distributes its products within the domestic market and to overseas markets.
Employees
2,350
Date Price Change Volume
26-11-16 CN¥2.840 -1.39% 86,104,320
26-11-16 CN¥2.880 -1.71% 91,021,084
26-11-13 CN¥2.930 -3.62% 140,547,205
26-11-12 CN¥3.040 -0.98% 134,716,235
26-11-11 CN¥3.070 +0.33% 113,169,172

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Harbin Gloria Pharmaceuticals Co., Ltd
  1. Stock Market
  2. Stocks
  3. 002437 Stock